1. Marzo A. Open questions on bioequivalence: some problems and some solutions. Pharmacol Res 1999; 40: 357–68
2. EMEA. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98, 2001 Jul 26 [online]. Available from URL: http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf [Accessed 2003 Sep 9]
3. US Dept of Health and Human Services. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products: general conditions — Draft Guidance distributed by US Dept of Health and Human Services, FDA, Center for Drug Evaluation and Research, 2002 Jul 11 [online]. Available from URL: http://www.fda.gov/OHRMS/DOCKETS/98fr/071102e.pdf [Accessed 2003 Sep 9]
4. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984; 9: 136–56
5. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet 1985; 10: 187–215